{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T16:24:17Z","timestamp":1771259057090,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T00:00:00Z","timestamp":1577664000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T00:00:00Z","timestamp":1577664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Mundipharma Pharmaceuticals (FRM-MA-006)."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of non-Hodgkin\u2019s lymphomas with poor clinical outcomes. Pralatrexate showed efficacy and safety in recurrent or refractory PTCLs. The purpose or this study was to investigate the efficacy and safety of pralatrexate in relapsed or refractory PTCLs in real-world practice. This was an observational, multicenter, retrospective analysis. Between December 2012 and December 2016, a total of 38 patients with relapsed or refractory PTCLs were treated with pralatrexate at 10 tertiary hospitals in Korea. Patients received an intravenous infusion of pralatrexate at a dose of 30\u2009mg\/m<jats:sup>2<\/jats:sup>\/week for 6 weeks on a 7-week schedule. Modified dosing and\/or scheduling was allowed according to institutional protocols. Median patient age was 58 years (range, 29\u201380 years) and the most common subtype was peripheral T-cell lymphoma, not otherwise specified (n\u2009=\u200923, 60.5%). The median dosage of pralatrexate per administration was 25.6\u2009mg\/m<jats:sup>2<\/jats:sup>\/wk (range, 15.0\u201333.0\u2009mg\/m<jats:sup>2<\/jats:sup>\/wk). In intention-to-treat analysis, 3 patients (7.9%) showed a complete response and 5 patients (13.2%) showed a partial response, resulting in an overall response rate (ORR) of 21.1%. The median duration of response was 7.6 months (range, 1.6\u201324.3 months). The median progression-free survival (PFS) was 1.8 months (95% confidence interval [CI], 1.7\u20131.8 months) and the median overall survival was 7.7 months (95% CI, 4.4\u20139.0 months). The most common grade 3\/4 adverse events were thrombocytopenia (n\u2009=\u200913, 34.2%), neutropenia (n\u2009=\u20097, 23.7%), and anemia (n\u2009=\u20097, 18.4%). Our study showed relatively lower ORR and shorter PFS in patients with recurrent or refractory PTCLs treated with pralatrexate in real-world practice. The toxicity profile was acceptable and manageable. We also observed significantly lower dose intensity of pralatrexate in real-world practice.<\/jats:p>","DOI":"10.1038\/s41598-019-56891-0","type":"journal-article","created":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T11:02:44Z","timestamp":1577703764000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1363-9332","authenticated-orcid":false,"given":"Jung Yong","family":"Hong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dok Hyun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Eun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho Sup","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeon-Seok","family":"Eom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Yeop","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youngil","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Soo","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Cheol","family":"Jo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo-Jeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-Hee","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won-Sik","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong-Ho","family":"Won","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheolwon","family":"Suh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,30]]},"reference":[{"key":"56891_CR1","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","volume":"15","author":"KJ Savage","year":"2004","unstructured":"Savage, K. J., Chhanabhai, M., Gascoyne, R. D. & Connors, J. M. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 15, 1467\u20131475 (2004).","journal-title":"Ann Oncol"},{"key":"56891_CR2","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose, J., Armitage, J. & Weisenburger, D. & International, T. C. L. P. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26, 4124\u20134130 (2008).","journal-title":"J Clin Oncol"},{"key":"56891_CR3","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1023\/A:1008439620513","volume":"9","author":"E Campo","year":"1998","unstructured":"Campo, E. et al. Report of the European Task Force on Lymphomas: workshop on peripheral T-cell lymphomas. Ann Oncol 9, 835\u2013843 (1998).","journal-title":"Ann Oncol"},{"key":"56891_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-016-0267-0","volume":"9","author":"Y Zhang","year":"2016","unstructured":"Zhang, Y., Xu, W., Liu, H. & Li, J. Therapeutic options in peripheral T cell lymphoma. J Hematol Oncol 9, 37 (2016).","journal-title":"J Hematol Oncol"},{"key":"56891_CR5","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.ctrv.2014.08.001","volume":"40","author":"B Coiffier","year":"2014","unstructured":"Coiffier, B. et al. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma. Cancer Treat Rev 40, 1080\u20131088 (2014).","journal-title":"Cancer Treat Rev"},{"key":"56891_CR6","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1182\/blood-2013-12-516245","volume":"123","author":"AJ Moskowitz","year":"2014","unstructured":"Moskowitz, A. J., Lunning, M. A. & Horwitz, S. M. How I treat the peripheral T-cell lymphomas. Blood 123, 2636\u20132644 (2014).","journal-title":"Blood"},{"key":"56891_CR7","doi-asserted-by":"publisher","first-page":"4357","DOI":"10.1200\/JCO.2008.20.8470","volume":"27","author":"OA O\u2019Connor","year":"2009","unstructured":"O\u2019Connor, O. A. et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol 27, 4357\u20134364 (2009).","journal-title":"J Clin Oncol"},{"key":"56891_CR8","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.12688\/f1000research.12573.1","volume":"6","author":"JH Yi","year":"2017","unstructured":"Yi, J. H., Kim, S. J. & Kim, W. S. Recent advances in understanding and managing T-cell lymphoma. F1000Res 6, 2123 (2017).","journal-title":"F1000Res"},{"key":"56891_CR9","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","volume":"33","author":"OA O\u2019Connor","year":"2015","unstructured":"O\u2019Connor, O. A. et al. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. J Clin Oncol 33, 2492\u20132499 (2015).","journal-title":"J Clin Oncol"},{"key":"56891_CR10","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41571-018-0163-3","volume":"16","author":"D Killock","year":"2019","unstructured":"Killock, D. ECHELON-2 - brentuximab raises PTCL outcomes to new levels. Nat Rev Clin Oncol 16, 145 (2019).","journal-title":"Nat Rev Clin Oncol"},{"key":"56891_CR11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","volume":"393","author":"S Horwitz","year":"2019","unstructured":"Horwitz, S. et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet 393, 229\u2013240 (2019).","journal-title":"Lancet"},{"key":"56891_CR12","doi-asserted-by":"publisher","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","volume":"117","author":"RL Piekarz","year":"2011","unstructured":"Piekarz, R. L. et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 117, 5827\u20135834 (2011).","journal-title":"Blood"},{"key":"56891_CR13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3960\/jslrt.56.135","volume":"56","author":"N Kawano","year":"2017","unstructured":"Kawano, N. et al. The Impact of a Humanized CCR4 Antibody (Mogamulizumab) on Patients with Aggressive-Type Adult T-Cell Leukemia-Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation. J Clin Exp Hematop 56, 135\u2013144 (2017).","journal-title":"J Clin Exp Hematop"},{"key":"56891_CR14","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","volume":"26","author":"Y Shi","year":"2015","unstructured":"Shi, Y. et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol 26, 1766\u20131771 (2015).","journal-title":"Ann Oncol"},{"key":"56891_CR15","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","volume":"29","author":"OA O\u2019Connor","year":"2011","unstructured":"O\u2019Connor, O. A. et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 29, 1182\u20131189 (2011).","journal-title":"J Clin Oncol"},{"key":"56891_CR16","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow, S. H. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127, 2375\u20132390 (2016).","journal-title":"Blood"},{"key":"56891_CR17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s11523-019-00630-y","volume":"14","author":"X Hong","year":"2019","unstructured":"Hong, X. et al. Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study. Target Oncol 14, 149\u2013158 (2019).","journal-title":"Target Oncol"},{"key":"56891_CR18","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1111\/cas.13340","volume":"108","author":"D Maruyama","year":"2017","unstructured":"Maruyama, D. et al. Phase I\/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma. Cancer Sci 108, 2061\u20132068 (2017).","journal-title":"Cancer Sci"},{"key":"56891_CR19","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1182\/blood-2017-09-806737","volume":"131","author":"JE Amengual","year":"2018","unstructured":"Amengual, J. E. et al. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood 131, 397\u2013407 (2018).","journal-title":"Blood"},{"key":"56891_CR20","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/bjh.13855","volume":"172","author":"RH Advani","year":"2016","unstructured":"Advani, R. H. et al. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial. Br J Haematol 172, 535\u2013544 (2016).","journal-title":"Br J Haematol"},{"key":"56891_CR21","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson, B. D. et al. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17, 1244 (1999).","journal-title":"J Clin Oncol"},{"key":"56891_CR22","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson, B. D. et al. Revised response criteria for malignant lymphoma. J Clin Oncol 25, 579\u2013586 (2007).","journal-title":"J Clin Oncol"},{"key":"56891_CR23","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson, B. D. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32, 3059\u20133068 (2014).","journal-title":"J Clin Oncol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-56891-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-56891-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-56891-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T18:11:38Z","timestamp":1671300698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-56891-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,30]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["56891"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-56891-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,30]]},"assertion":[{"value":"2 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20302"}}